Omega Fund Iv, L.p. - Net Worth and Insider Trading

Omega Fund Iv, L.p. Net Worth

The estimated net worth of Omega Fund Iv, L.p. is at least $2 Million dollars as of 2024-05-05. Omega Fund Iv, L.p. is the 10% Owner of Paratek Pharmaceuticals Inc and owns about 779,802 shares of Paratek Pharmaceuticals Inc (PRTK) stock worth over $2 Million. Details can be seen in Omega Fund Iv, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Omega Fund Iv, L.p. has not made any transactions after 2016-06-27 and currently still holds the listed stock(s).

Transaction Summary of Omega Fund Iv, L.p.

To

Omega Fund Iv, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Omega Fund Iv, L.p. owns 5 companies in total, including Replimune Group Inc (REPL) , Translate Bio Inc (TBIO) , and Kezar Life Sciences Inc (KZR) among others .

Click here to see the complete history of Omega Fund Iv, L.p.’s form 4 insider trades.

Insider Ownership Summary of Omega Fund Iv, L.p.

Ticker Comapny Transaction Date Type of Owner
REPL Replimune Group Inc 2018-07-19 10 percent owner
TBIO Translate Bio Inc 2018-07-02 10 percent owner
KZR Kezar Life Sciences Inc 2018-06-20 10 percent owner
2016-06-27 10 percent owner
2014-02-11 10 percent owner

Omega Fund Iv, L.p. Latest Holdings Summary

Omega Fund Iv, L.p. currently owns a total of 1 stock. Omega Fund Iv, L.p. owns 779,802 shares of Paratek Pharmaceuticals Inc (PRTK) as of June 27, 2016, with a value of $2 Million.

Latest Holdings of Omega Fund Iv, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRTK Paratek Pharmaceuticals Inc 2016-06-27 779,802 2.23 1,738,958

Holding Weightings of Omega Fund Iv, L.p.


Omega Fund Iv, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Omega Fund Iv, L.p. has made a total of 0 transactions in Paratek Pharmaceuticals Inc (PRTK) over the past 5 years. The most-recent trade in Paratek Pharmaceuticals Inc is the acquisition of 461,538 shares on June 27, 2016, which cost Omega Fund Iv, L.p. around $6 Million.

Insider Trading History of Omega Fund Iv, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Omega Fund Iv, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Omega Fund Iv, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Omega Fund Iv, L.p. is 7.27%. GuruFocus also compares Omega Fund Iv, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Omega Fund Iv, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Omega Fund Iv, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Omega Fund Iv, L.p.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 3.83
Relative Return to S&P 500(%) -4.47

Omega Fund Iv, L.p. Ownership Network

Ownership Network List of Omega Fund Iv, L.p.

No Data

Ownership Network Relation of Omega Fund Iv, L.p.


Omega Fund Iv, L.p. Owned Company Details

What does Replimune Group Inc do?

Who are the key executives at Replimune Group Inc?

Omega Fund Iv, L.p. is the 10 percent owner of Replimune Group Inc. Other key executives at Replimune Group Inc include Chief Commercial Officer Christopher Sarchi , Chief Medical Officer Konstantinos Xynos , and Chief Financial Officer Emily Luisa Hill .

Replimune Group Inc (REPL) Insider Trades Summary

Over the past 18 months, Omega Fund Iv, L.p. made no insider transaction in Replimune Group Inc (REPL). Other recent insider transactions involving Replimune Group Inc (REPL) include a net sale of 66,624 shares made by Pamela Esposito , a net sale of 25,067 shares made by Tanya Lewis , and a net sale of 21,273 shares made by Sushil Patel .

In summary, during the past 3 months, insiders sold 0 shares of Replimune Group Inc (REPL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 174,192 shares of Replimune Group Inc (REPL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 174,192 shares.

Replimune Group Inc (REPL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Replimune Group Inc Insider Transactions

No Available Data

Omega Fund Iv, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Omega Fund Iv, L.p.. You might contact Omega Fund Iv, L.p. via mailing address: 888 Boylston St., Suite 1111, Boston Ma 02199.

Discussions on Omega Fund Iv, L.p.

No discussions yet.